Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Wednesday

Atea Pharmaceuticals (NASDAQ:AVIR) will likely be announcing its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Atea Pharmaceuticals Trading Down 1.6 %

Shares of AVIR stock opened at $3.09 on Monday. Atea Pharmaceuticals has a twelve month low of $2.75 and a twelve month high of $4.60. The stock has a market capitalization of $260.98 million, a price-to-earnings ratio of -1.49 and a beta of 0.19. The stock has a fifty day simple moving average of $3.19 and a two-hundred day simple moving average of $3.38.

Insiders Place Their Bets

In related news, Director Franklin M. Berger sold 359,606 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now directly owns 451,897 shares in the company, valued at $1,287,906.45. This represents a 44.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 17.80% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.